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CONFLICTING results have recently
been reported by various groups of
workers regarding the change in sensi-
tivity to bleomycin (BLM) which occurs
as cultured mammalian cells pass from
exponential growth into plateau phase.
Using various Chinese hamster cell lines,
Ray et al. (1973) and Barranco, Novak
and Humphrey (1973) have shown an
increased sensitivity to the drug, whereas
Mauro et al. (1974) have shown reduced
sensitivity. In our own studies using
the EMT6 mouse tumour cell line in
culture (Twentyman and Bleehen, 1973)
we originally found a reduced sensitivity
in plateau phase, but more recently
(Twentyman and Bleehen, 1975) we
have demonstrated that when the cells
have been in plateau phase for more than
10 days, the BLM sensitivity is greater
than that seen during exponential growth.
Furthermore, it appears that delayed
subculture following BLM treatment of
cells in vitro (Ray et al., 1973; Twentyman
and Bleehen, unpublished) or from a solid
tumour (Hahn et al., 1973) results in a
reduction in the cell killing effect of the
drug. One explanation for the finding
is repair of " potentially lethal damage "
(Ray et al., 1973; Hahn et al., 1973)
similar to that which has been found
following radiation treatment both in
vitro (Hahn and Little, 1972) and in
vivo (Little et al., 1973).
In a study of BCNU response both in
vitro and in vivo, Hagemann, Schenken
and Lesher (1973) have shown a change in
response with size of a mastocytoma
growing as a solid tumour in the mouse.
The change could not, however, be
accounted for by their observations on
exponential and plateau phase cells either
in vitro or as an ascites tumour.
In this paper we describe experiments
which have been carried out to investigate
possible changes in BLM sensitivity which
occur during the growth ofa solid tumour,
and also the ability of tumours of various
sizes to repair BLM damage upon delayed
subculture. These experiments have been
carried out in an attempt to assess the
possible significance for solid tumour
therapy of the various results which have
been obtained in vitro.
MATERIALS AND METHODS
The EMT6 cell line may be grown either
in vivo as a solid tumour or in vitro as a
monolayer (Rockwell, Kallman and Fajardo,
1972). In addition, assay of cell survival
following treatment in vivo may be assayed
by in vitro plating (Hahn et al., 1973).
Tumour transplantation was carried out
by the intradermal injection of 4 x 104
EMT6 cells which had been in culture for
about 20 days after being taken from the
previous animal tumour generation. At 8 or
9, 15, 22 or 35 days following transplantation,
groups of3 tumour bearing mice were treated
with BLM. The drug was injected intra-P. R. TWENTYMAN AND N. M. BLEEHEN
peritoneally in a volume of 0 5 ml of normal
saline either 2 or 24 h before killing the
animal and subsequent remnoval of the
tumour.
Tumours were removed aseptically imme-
diately after killing the animals. The tu-
mours from each group of 3 animals were
minced together in a glass petri dish using
fine curved scissors. A small volume of
Hank's solution was added, and the tumour
fragments were washed into a glass universal
containing 10 ml of Hank's solution with
0-1% added trypsin and a magnetic followTer,
the entire assembly being warmed to 37°C.
The universal was then placed on a magnetic
stirrer for 20 min at room temperature.
At the end of this time, the contents were
filtered through a P.T.F.E. funnel containing
cotton gauze into a plastic universal which
wN-as then centrifuged at 1000 rev/min for
10 min at 4°C. At the end of this time, the
supernatant was discarded, the cells re-
suspended in comnplete growth medium and
placed on ice. A count of morphologically
viable cells under phase contrast was then
carried out using a haemacytoineter, dilutions
wNere made and the cells w-ere plated.
The foregoing method was slightly modi-
fied for large (22 and 35 day) tumours.
'lthese tumnours, after mincing, were washed
into glass flasks containing 150 ml of Hanks'
solution plus 0.10/ trypsin at 37°C. The
solution wNas then stirred at room temperature
on a motor with a razor blade attached for
20 min. Following filtration, centrifugation
was carried out in glass centrifuge vessels.
The sample of the cell suspension was
diluted in wNhite cell fluid before counting,
as tumours of this size contain a large
proportion of red blood cells.
The medium used throughout these
studies was Eagle's MEM with Earle's salts
and supplemented with 20% calf serum. In
addition to the tumour cells, 104 cells from a
continuous culture subline of EMT6 were
treated wAith 10 krad irradiation and plated
in each dish as a feeder layer. The dishes
used M-ere 50 mm plastic tissue culture
dishes (Sterilin Ltd). These were placed into
plastic boxes, gassed with a mixture of
950% air and 5% CO2 and kept at high
humidity and at 37 C for 13-14 days.
At the end of this time, the dishes were
washed, fixed in 950o alcohol, stained wNith
crystal violet and colonies containing more
than 50 cells wN-ere counted. Plating effi-
ciences of untreated tumour cells varied
betwreen about 10% and 500,,.
RESULTS
Growth parameters for the EMT6
tumour at various sizes have been deter-
mined in our laboratory by Dr J. V.
Watson (personal communication) and are
shown in the Table. Experiments to
determine the cell proliferation kinetic
parameters are presently being carried
out.
TABLE.-Growth Paranmeters for EMT6
Solid Tumours Followiny Inoculation of
4 X 104 Cells
Mfean ttumour- volume
(mm3)
Day after (95°O confideince limits
inoculatioin in parentheses)
8-9
15
22
:35
7 (5 6-9 4)
48 (37-60)
161 (129-204)
660 (500-887)
Tumour
doubling time
(days)
1 5
3-2
4-8
8-3
Figures are taken from a composite growth
cutrve for 320 individual tumours in 7 dlifferent
exper-iments. Doubling time valtues are estimate(d
firom taingenits to the curve.
Bleomycin response
The response to bleomycin of tumours
of various sizes shows essentially the same
picture quantitatively and qualitatively
including the spread of data. The figure
shows the data for the 15-day old tumour.
For each tumour size, the response curve
is biphasic, with an initial fall to a
surviving fraction of about 10% being
achieved by a dose of 1 mg/kg and a
much less steep fall above this dose.
The lines drawn on the graph lie ap-
proximately through the mean surviving
value obtained at each dose. The spread
of individual values at each dose is,
however, considerable.
When tumour removal and plating
were delayed until 24 h after bleomycin
administration, the drug was found to
have had little or no effect on cell survival
at any of the tumour sizes.
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Ftc:. Survivinig fraction of EMT6 tumouIr
cells expose(l io vivo to BLM at 15 days
following ttumour implantation. Graphs
drawn for 8-9 day, or 22 or 35 (lay o0l
tumouirs show essentially the same picture
quantitatively an(l qualitatively, including
the spIrea(l of data. Different symbols
represent dlifferent experiments. The 3
poinlts near the top of the diagram an(d the
dotted line are for BLM a(dministration at
24 h before suirvival assay. The remaining
poinits and the solid line are foi BLM
administration at 2 h before survival
assay. Error bars iepresent ±2 s.c. mean
colony count on 4 replicate plates. Platiing
efficienicies: 0, 46%; 0, 12%; *, 46%o;
E], 280c; A, 34%.
DISCUSSION
The results presented here are in
good agreement with those that have
been reported previously by Hahn et
al. (1973) using the EMT6 tumour at a
size of 100-150 mm3 (which corresponds
to the 22-day tumours in our work).
Wre consider that their data can be best
represented by a rapid initial fall to a
surviving fraction of 7-11% and a subse-
quent more gradual fall which extends
at least to a dose of 80 mg/kg.
In ouir stu(ly, the change in tumour
size is over a 100-fold range in volume
and this represents the possible working
range for a tumour of this type using
conventional techniques. Before Day 8
the tumours are difficult to locate and
even when many such tumours are
trypsinized together the cell yield is low.
At later times than 35 days, the tumours
become increasingly necrotic with large
volumes of dead tissue within the tumour
and surface ulceration. It appears, how-
ever, that over this range of sizes no
change in response to BLM can be
shown.
It is difficult to interpret this finding
with regard to the various factors known
to influence the response of solid tumours
to cytotoxic drugs. The work of Bar-
ranco et al. (1973) has shown that the
response of plateau phase cells in culture
can be quite different from that which
could have been predicted from their
cell cycle distribution. This finding
clearly implies that some other factor is
involved in determining the response of
such cells. Changes in such factors as
the ability of the cells to take up the
drug and changes in the efficiency of
damage repair mechanisms are only two
of the more obvious candidates. It is
also necessary to take into account, when
considering the drug response of solid
tumours, the extent to which the drug
is able to diffuse from the vascular
supply to those viable cells located some
distance away from the vessels. Hage-
mann and his associates (1973) have
suggested that the much lower sensitivity
to BCNU exhibited by P815 x 2 masto-
cytoma cells in a solid tumour compared
with the ascites form may be explained
on the basis of drug availability. In
the EMT6 solid tumour response measured
2 h after BLM we have obtained a bi-
phasic curve with the inflexion at a
surviving fraction of about 10%0 and a
dose of 1 mg/kg.
If this is compared witlh our in vitro
results for exponential phase cells (about
30%0 surviving fraction at a dose of
10 pig/ml) (Twentyman anid Bleehen,
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1973) or late plateau phase cells (sur-
viving fraction of about 20% at 10 /tg/ml)
(Twentyman and Bleehen, 1975) it may
be seen that the sensitivity in vivo is
at least as great as could have been
predicted from the in vitro data. It
may well be, therefore, that drug avail-
ability does not represent a problem, so
far as BLM is concerned, in this tumour
system.
The ability of cells to repair BLM
damage if left in situ following exposure
to the drug has been discussed by Hahn et
at. (1973). Our results indicate that this
ability is possessed by cells in solid
tumours at all sizes and that over 80%
of the damage is repaired between 2 and
24 h. It is, however, possible that a
drug induced, partial synchronization of
cells into phases of the cell cycle with
relatively high plating efficiency may
contribute towards the effect of delayed
subculture following BLM. This finding
is different from that demonstrated by
Little et al. (1973) for radiation damage
when delayed subculture was found to
result in more enhancement of survival
in large than in small NCTC solid tumours.
In this situation, however, the amount
of repair is small compared with that
following BLM treatment.
It is important to remember that
even the smallest tumours which we have
studied (approximately 7 mm3) represent
a late stage of the growth of a solid
tumour from an inoculum of a few cells.
It is very possible that quite different
responses to BLM would be shown by
solid tumours at earlier stages of growth.
It is our intention to extend our studies
to such tumours using indirect techniques
of survival assay.
This work was partly financed by a
grant from theCancerResearch Campaign
which we gratefully acknowledge. Bleo-
mycin was kindly supplied by Lundbeck
Ltd. WethankMiss S. Kellerfortechnical
assistance.
REFERENCES
BAmRANco, S. C., NovAx, J. K. & HUMPHREY,
R. M. (1973) Response of Mammalian Cells
following Treatment with Bleomycin and 1,3-
Bis(2-chloroethyl)-l-nitrosourea during Plateau
Phase. Cancer Re8., 33, 691.
HAGEMANN, R. F., SCHENKEN, L. L. & LESHER, S.
(1973) Tumor Chemotherapy: Efficacy Dependent
on Mode of Growth. J. natn. Cancer Inst.,
50, 467.
HAHN, G. M. & LITTLE, J. B. (1972) Plateau Phase
Cultures of Mammalian Cells: An in vitro Model
for Human Cancer. Curr. top. Radiat. Res.,
8, 39.
HAHxN, G. M., RAY, G. R., GORDON, L. F. &Y KALL-
MAN, R. F. (1973) Response of Solid Tumor
Cells to Chemotherapeutic Agents in vivo. Cell
Survival after 2 and 24 hour Exposure. J.
natn. Cancer Inst., 50, 529.
LITTLE, J. B., HAHN, G. M., FRINDEL, E. & TUBIANA,
M. (1973) Repair of Potentially Lethal Radiation
Damage in vitro and in vivo. Radiology, 106,
689.
MAURO, F., FALPo, B., BRIGANTI, G., ELLI, R. &
ZuPi, G. (1974) Effects of Anti-neoplastic Drugs
on Plateau Phase Cultures of Mammalian Cells.
2. Effects of Bleomycin and Hydroxyurea. J.
natn. Cancer In8t., 52, 715.
RAY, G. R., HAHN, G. M., BAGSEHAW, M. A. &
KURKJIAN, S. (1973) Cell Survival and Repair of
Plateau-phaseCulturesafterChemotherapy-Rele-
vance to Tumor Therapy and to the in vitro
Screening of New Agents. Cancer Chemother.
Rep., Pt 1, 57, 473.
ROCKWELL, S. C., KALLmAN, R. F. & FAJARDO,
L. F. (1972) Characteristics of a Serially Trans-
planted Mouse Mammary Tumor and its Tissue-
culture-adapted Derivative. J. natn. Cancer
Inst., 49, 735.
TWENTYMAN, P. R. & BLEEHEN, N. M. (1973) The
Sensitivity of Cells in Exponential and Stationary
Phases of Growth to Bleomycin and to 1,3-
Bis(2-Chloroethyl)-1-nitrosourea. Br. J. Cancer,
28, 500.
TWENTYMAN, P. R. & BLEEHEN, N. M. (1975)
Changes in Sensitivity to Radiation and to
Bleomycin Occurring During the Life-history of
Monolayer Cultures of a Mouse Tumour Cell
Line. Br. J. Cancer, 31. In the press.